Cefixime in urinary tract infections in women

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Urinary tract infections (UTIs) remain one of the most common bacterial infections in outpatient practice, particularly among women of reproductive age and pregnant patients. One of the therapeutic options for UTIs is cefixime, a broad-spectrum third-generation cephalosporin. Cefixime demonstrates high antimicrobial activity with a minimal number of adverse effects, which explains the absence of contraindications for its use during pregnancy.

Cefixime has high oral bioavailability, is often resistant to β-lactamases, and ensures sufficient urinary concentration when administered at 400 mg once daily. Pharmacokinetic parameters remain stable during pregnancy, while preclinical studies indicate extremely low penetration into fetal tissues and breast milk (<1% of the dose).

The dispersible formulation Cefixime EXPRESS provides additional benefits for pregnant women due to ease of administration, improved tolerability and adherence. Cefixime EXPRESS in dispersible form represents a modern drug for the treatment of both acute uncomplicated cystitis and acute uncomplicated pyelonephritis, particularly in outpatient settings. It combines proven efficacy with convenient dosing, good tolerability, and a rapid clinical response, making it a reasonable treatment choice, especially when first-line drugs are contraindicated or in cases of resistance to other antibiotics.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Olga Nesterova

FGBOU VO Lomonosov Moscow State University

Хат алмасуға жауапты Автор.
Email: oy.nesterova@gmail.com
ORCID iD: 0000-0003-3355-4547
SPIN-код: 9662-7522

Ph.D., urologist, senior researcher, Urology and Andrology Department, University Clinic, Senior Lecturer, Department of Urology and Andrology, Faculty of Fundamental Medicine

Ресей, Moscow

Әдебиет тізімі

  1. Analogue-based Drug Discovery. by János Fischer, Ganellin C.R. Analogue-based Drug Discovery. Chemistry International – Newsmagazine for IUPAC. 2010;32(4):12–15.
  2. Macedonia N. Treatment of upper respiratory tract infections with third. 2021;4:143–148.
  3. Ajmal M., Zamir A., Rehman A.U. et al. Clinical pharmacokinetics of cefixime: a systematic review. Xenobiotica; the fate of foreign compounds in biological systems. England. 2023;53(3):149–162.
  4. Brogden R.N., Campoli-richards D.M. Cefixime. A Review of its Antibacterial Activity , Pharmacokinetic Properties and Therapeutic Potential. Drugs. 1989;38(4):524–550.
  5. Ghazy E., Al-Tamimi D., Al-Mahroos M. et al. Pharmacokinetics and Bioequivalence Study of Two Formulations of Cefixime Suspension. Journal Of Advanced Pharmacy Education And Research. 2021;11:170–177.
  6. Sperling M.I., Sperling N.V., Neimark A.I. et al. Modern Approaches to the Diagnosis and Treatment of Urinary Tract Infections During Pregnancy. Urology. 2024;4:116–12. Russian (Шперлинг М.И., Шперлинг Н.В., Неймарк А.И. и др. Современные подходы к диагностике и лечению инфекций мочевыводящих путей во время беременности. Урология. 2024;4:116–122).
  7. Abdullah A., Mutmainnah M., Wikantyasning E. Cocrystals of Cefixime with Nicotinamide: Improved Solubility, Dissolution, and Permeability. Indonesian Journal of Pharmacy. 2022. P. 395–401.
  8. Liu X.D., Xie L., Gao J.P. et al. Cefixime absorption kinetics after oral administration to humans. European journal of drug metabolism and pharmacokinetics. France. 1997;22(2):185–188.
  9. Danafar H. A quick and easy high performance liquid chromatography method for evaluation of cefixime in human plasma. Pharmaceutical and Biomedical Research. 2015;1:29–39.
  10. Barré J. [Pharmacokinetic properties of cefixime]. Presse medicale (Paris, France : 1983). France. 1989;18(32):1578–1582.
  11. Faulkner R.D., Yacobi A., Barone J.S. et al. Pharmacokinetic profile of cefixime in man. The Pediatric infectious disease journal. United States. 1987;6(10):963–970.
  12. Dhib M., Moulin B., Leroy A. et al. Relationship between renal function and disposition of oral cefixime. European journal of clinical pharmacology. Germany. 1991;41(6):579–583.
  13. A prospective, open-label, randomized, crossover study evaluating the comparative pharmacokinetics and bioequivalence of Cefixime EXPRESS (INN cefixime), 400 mg dispersible tablets (CJSC LEKKO, Russia), and Suprax Solutab (INN cefixime), 400 mg dispersible tablets (Astellas Pharma Europe B.V., Netherlands) in healthy volunteers. Russian (Проспективное открытое рандомизированное перекрестное исследование по изучению сравнительной фармакокинетики и биоэквивалентности препаратов Цефиксим ЭКСПРЕСС (МНН: цефиксим), таблетки диспергируемые, 400 мг (ЗАО «ЛЕККО», Россия) и Супракс® Солютаб® (МНН: цефиксим), таблетки диспергируемые, 400 мг (Астеллас Фарма Юроп Б.В., Нидерланды) у здоровых добровольцев).
  14. List of interchangeable medicinal products authorized by the Ministry of Health of the Russian Federation. Russian (Перечень взаимозаменяемых лекарственных препаратов, утверждённый МЗ РФ).
  15. Faulkner R.D., Sia L.L., Barone J.S. et al. Bioequivalency of oral suspension formulations of cefixime. Biopharmaceutics & drug disposition. England. 1989;10(2):205–211.
  16. Teterina T.A., Apolikhina I.A. A differentiated approach to antibacterial therapy of cystitis in women. Diagnostics and Treatment Algorithms. 2023. Suppl. 9. p. 47–52. Russian (Тетерина Т.А., Аполихина И.А. Дифференцированный подход к антибактериальной терапии цистита у женщин. Алгоритмы диагностики и лечения. 2023. Приложение № 9. C. 47–52).
  17. Cefixime-EXPRESS. Instructions for medical use of the drug. 21.12.2023. Access mode: https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=7b401e42-15a2-431a-ae6f-76f92ee2a268. Russian (Цефиксим-ЭКСПРЕСС. Инструкция по медицинскому применению лекарственного препарата. 21.12.2023. Режим доступа: https://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=7b401e42-15a2-431a-ae6f-76f92ee2a268).
  18. Apolikhin O.I., Wagenlehner F., Voytko D.A. et al. Epidemiological study of the prevalence of cystitis in women of the Voronezh region. Experimental and Clinical Urology. 2021;14(1):10–18. Russian (Аполихин О.И., Вагенленер Ф., Войтко Д.А. и др. Эпидемиологическое исследование распространенности цистита у женщин Воронежской области. Экспериментальная и клиническая урология. 2021;14(1):10–18).
  19. Clinical guidelines. Acute cystitis. Ministry of Health of the Russian Federation. 2024. Russian (Клинические рекомендации. Острый цистит. Министерство здравоохранения Российской Федерации. 2024).
  20. Vakilzadeh M.M., Heidari A., Mehri A. et al. Antimicrobial Resistance among Community-Acquired Uropathogens in Mashhad, Iran. Journal of environmental and public health. United States. 2020;2020:3439497.
  21. Martin D., Fougnot S., Grobost F. et al. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013. The Journal of infection. England. 2016;72(2):201–206.
  22. Sakata T., Miyake K., Kinukawa T. et al. [Clinical evaluation of usefulness of cefixime (200 mg administered once daily) in the treatment of acute uncomplicated cystitis]. Hinyokika kiyo. Acta urologica Japonica. Japan. 1992;38(11):1337–1342.
  23. Asbach H.W. Single dose oral administration of cefixime 400mg in the treatment of acute uncomplicated cystitis and gonorrhoea. Drugs. New Zealand. 1991;42(Suppl 4):10–13.
  24. Kameoka H., Takano Y., Miyoshi S. et al. [Clinical experience with cefixime in urinary tract infections]. The Japanese journal of antibiotics. Japan. 1989;42(12):2540–2547.
  25. Togashi M., Kubota M., Nagamori S. et al. [Clinical evaluation of cefixime in the treatment of acute uncomplicated cystitis]. Hinyokika kiyo. Acta urologica Japonica. Japan. 1989;35(6):1083–1087.
  26. Weir M., Brien J. Adolescent urinary tract infections. Adolescent medicine (Philadelphia, Pa.). United States. 2000;11(2):293–313.
  27. Galkin V.V., Dovgan E.V., Kozlov S.N., Rafalsky V.V. Cefixime versus ciprofloxacin in acute uncomplicated cystitis: a clinical and economic study. Clinical Microbiology and Antimicrobial Chemotherapy. 2012;14(1):59–66. Russian (Галкин В.В., Довгань Е.В., Козлов С.Н., Рафальский В.В.. Цефиксим в сравнении с ципрофлоксацином при остром неосложненном цистите: клинико-экономическое исследование. Клиническая микробиология и антимикробная химиотерапия. 2012;14(1):59–66).
  28. Galkin V.V., Maleev I.V., Dovgan E.V. et al. Efficacy and Safety of Cefixime and Ciprofloxacin in Acute Cystitis (Multicenter Randomized Study). Urologiia. 2011;1:13–16. Russian (Галкин В.В., Малеев И.В., Довгань Е.В. и др. Эффективность и безопасность цефиксима и ципрофлоксацина при остром цистите (Многоцентровое рандомизированное исследование). Урология. 2011;1:13–16).
  29. Raz R., Rottensterich E., Leshem Y. et al. Double-blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women. Antimicrobial agents and chemotherapy. United States. 1994;38(5):176–1177.
  30. Palagin I.S., Shevelev A.N. Modern approaches to the choice of antibacterial therapy in the treatment of acute uncomplicated cystitis. Effective Pharmacotherapy in Urology. 2010;4:36–41. Russian (Палагин И.С., Шевелев А.Н. Современные подходы к выбору антибактериальной терапии при лечении острых неосложненных циститов. Эффективная фармакотерапия в урологии. 2010;4:36–41).
  31. Laurent O.B., Sinyakova L.A., Kosova I.V. Modern approaches to the diagnosis and treatment of acute non-obstructive pyelonephritis in women. Medical Council. 2008;1–2:27–31. Russian (Лоран О.Б., Синякова Л.А., Косова И.В. Современные подходы к диагностике и лечению острого необструктивного пиелонефрита у женщин. Медицинский совет. 2008;1–2:27–31).
  32. Kogan M.I., Ivanov S.N., Naboka Yu.L. Current issues of epidemiology, etiology, as well as risk factors and predisposing conditions of acute pyelonephritis (part 1). Urologiia. 2021;2:109–115. Russian (Коган М.И., Иванов С.Н., Набока Ю.Л. Актуальные вопросы эпидемиологии, этиологии, а также факторы риска и предрасполагающие состояния острого пиелонефрита (часть 1). Урология. 2021;2:109–115).
  33. Clinical guidelines. Acute pyelonephritis. Ministry of Health of the Russian Federation. 2024. Russian (Клинические рекомендации. Острый пиелонефрит. Министерство здравоохранения Российской Федерации. 2024).
  34. Bader M.S., Loeb M., Leto D. et al. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgraduate medicine. England, 2020;132(3):234–250.
  35. Pistiki A., Tsaganos T., Galani I. et al. In Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections. Infectious diseases and therapy. New Zealand. 2015;4(4): 425–432.
  36. Palagin I.S., Sukhorukova M.V., Dekhnich A.V. et al. Antibiotic resistance of pathogens of community-acquired urinary tract infections in Russia: results of the multicenter study DARMIS-2018. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(2):134–146. Russian (Палагин И.С., Сухорукова М.В., Дехнич А.В. и др. Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018». Клиническая микробиология и антимикробная химиотерапия. 2019;21(2):134–146).
  37. Moreno-Martínez A., Mensa J., Martínez J.A. et al. [Cefixime versus amoxicillin plus netilmicin in the treatment of community-acquired non-complicated acute pyelonephritis]. Medicina clinica. Spain. 1998;111(14):521–524.
  38. François P., Croizé J., Bost C. et al. [Comparative study of cefixime versus amoxicillin-clavulanic acid combination in the oral treatment of urinary tract infections in children]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. France. 1995;2(2):136–142.
  39. Naber K.G. [Cefixime in urinary tract infections. (Specific studies and literature review)]. Infection. Germany. 1990;18(Suppl 3):S132-9.
  40. Modai J. Efficacy and tolerability of cefixime in urinary tract infections in adults. A French multicentric study. Presse medicale (Paris, France : 1983). France. 1989;18(32):1614–1616.
  41. Sonoda T., Matsuda M., Nakano E. et al. Clinical evaluation of cefixime (CFIX) in the treatment of urinary tract infection. Hinyokika kiyo. Acta urologica Japonica. Japan. 1989;35(7):1267–1275.
  42. Fujisawa M., Sasaki M., Fujii H. et al. [Treatment of urinary tract infection with cefixime]. Hinyokika kiyo. Acta urologica Japonica. Japan. 1989;35(11):1989–1992.
  43. Roche G. Cefixime, the first oral third-generation cephalosporin. Presse medicale (Paris, France : 1983). France. 1989;18(32):1541–1544.
  44. Moustafa F., Nguyen G., Mathevon T. et al. Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department. The Journal of antimicrobial chemotherapy. England. 2016;71(6):1660–1664.
  45. Rodríguez-Gascón A., Aguirre-Quiñonero A., Canut-Blasco A. Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective. Enfermedades Infecciosas y Microbiología Clínica. 2020;38(7):306–311.
  46. Macejko A.M., Schaeffer A.J. Asymptomatic bacteriuria and symptomatic urinary tract infections during pregnancy. The Urologic clinics of North America. United States. 2007;34(1):35–42.
  47. Habak P.J., Carlson K., Griggs Robert P J. Urinary Tract Infection in Pregnancy. Treasure Island (FL), 2025.
  48. Halperin-Walega E., Batra V.K., Tonelli A.P. et al. Disposition of cefixime in the pregnant and lactating rat. Transfer to the fetus and nursing pup. Drug metabolism and disposition: the biological fate of chemicals. Netherlands. 1988;16(1):130–134.
  49. Ozyüncü O., Beksac M.S., Nemutlu E. et al. Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime. The journal of obstetrics and gynaecology research. Australia. 2010;36(3):484–487.
  50. Clinical guidelines. Urinary tract infections in pregnancy. Ministry of Health of the Russian Federation. https://cr.minzdrav.gov.ru/view-cr/719_1. Russian (Клинические рекомендации. Инфекции мочевых путей при беременности. Министерство здравоохранения Российской Федерации. https://cr.minzdrav.gov.ru/view-cr/719_1).
  51. Mohapatra S., Venugopal S.J., Kalaivani M. et al. Antibiotic resistance of uropathogens among the community-dwelling pregnant and nonpregnant female: a step towards antibiotic stewardship. BMC infectious diseases. England. 2022;22(1):939.
  52. Kapasheva Sh.Kh. Gestational Pyelonephritis: Experience with Cefixime. Vestnik PGU. 2013;2:57–6. Russian (Капашева Ш.Х. Гестационный пиелонефрит: опыт применения цефиксима. Вестник ПГУ. 2013;2:57–65).
  53. de Souza H.D., Diório G.R.M., Peres S.V. et al. Bacterial profile and prevalence of urinary tract infections in pregnant women in Latin America: a systematic review and meta-analysis. BMC pregnancy and childbirth. England. 2023;23(1):774.
  54. Azami M., Jaafari Z., Masoumi M. et al. The etiology and prevalence of urinary tract infection and asymptomatic bacteriuria in pregnant women in Iran: a systematic review and Meta-analysis. BMC urology. England. 2019;19(1):43.
  55. Angelescu K., Nussbaumer-Streit B., Sieben W. et al. Benefits and harms of screening for and treatment of asymptomatic bacteriuria in pregnancy: a systematic review. BMC pregnancy and childbirth. England. 2016;16(1):336.
  56. Mayomba C., Matovelo D., Kiritta R. et al. Asymptomatic bacteriuria and its associated fetomaternal outcomes among pregnant women delivering at Bugando Medical Centre in Mwanza, Tanzania. PloS one. United States. 2024;19(10):e0303772.
  57. Rafalsky V.V., Dovgan E.V., Kozyrev Yu.V. et al. Efficacy and safety of cefixime and amoxicillin/clavulanate in the treatment of asymptomatic bacteriuria in pregnant women: a multicenter randomized prospective study. Urologiia. 2013;5:26–28. Russian (Рафальский В.В., Довгань Е.В., Козырев Ю.В. и др. Эффективность и безопасность цефиксима и амоксициллина/клавуланата при лечении бессимптомной бактериурии у беременных: многоцентровое рандомизированное проспективное исследование. Урология. 2013;5:26–28).
  58. Degtyareva E.I., Romanova D.G. Urinary Tract Infections in Pregnant Women. Medical Council. 2024;18(4):67–72. Russian (Дегтярева Е.И., Романова Д.Г. Инфекции мочевыводящих путей у беременных. Медицинский совет. 2024;18(4):67–72).
  59. Shabanova N.E. Urinary Tract Infections in Pregnant Women. Obstetrics and Gynecology. 2024;8:137–142. Russian (Шабанова Н.Е. Инфекции мочевыводящих путей у беременных. Акушерство и гинекология. 2024;8:137–142).

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Drawing. The probability of achieving an effective concentration of cefixime (RTA) and the probability that the drug will effectively destroy the bacterial population (CFR) for the three dosage regimens of cefixime. Adapted from [45]

Жүктеу (193KB)
Метадеректер

© Bionika Media, 2025